ClinicalTrials.gg
CompletedNCT07302737Updated Nov 12, 2026

Delirium and Heart Failure

An observational study in Heart Failure and Delirium Confusional State, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Ain Shams University · Observational

How we know

Updated Nov 12, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
70
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Heart Failure by Ain Shams University — 1 open to participants now, 3 under way, none of them phase 3. Heart Failure · Ain Shams University.

Started
2026
the only one that year
Observational
4 of 10
none open now
Registered
9th of 10
by date

Among the 10 studies in Heart Failure by Ain Shams University, this one is the only one that started in 2026, is one of 4 observational ones, and was the 9th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

1 of the 10 studies in Heart Failure by Ain Shams University is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Heart Failure by Ain Shams University, or all of them as a file.
02

Study summary

Biomarkers such as Systemic Immune-Inflammation Index (SII) and TG/Glucose Ratio (TyG) have shown promise in predicting delirium, reflecting the roles of inflammation and metabolic disturbances in its pathophysiology. This study aims to compare the predictive value of SII and the TyG ratio among other chemical and physiological biomarkers for diagnosing delirium and detecting its severity in older adults with heart failure. These biomarkers reflect different pathophysiological pathways implicated in delirium, including inflammation, cardiovascular stress, and metabolic dysfunction. By evaluating their individual and combined predictive abilities, this research seeks to identify potential tools for early identification of patients at high risk for delirium

03

Conditions studied

  • Heart Failure
  • Delirium Confusional State

Keywords

  • Heart failure
  • delirium
  • older adults
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

hospitalized older adults with heart failure

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Heart failure stage C

Exclusion criteria

Exclusion Criteria:

  1. cognitive impairment
  2. Major Neurological Conditions: (e.g., stroke, traumatic brain injury).
  3. Hematological diseases that affect , neutrophil, and lymphocyte counts.
  4. Cardiogenic Shock
  5. Sepsis
  6. Ongoing Treatment with , or
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
70 participants (actual)
Patient registry
No

Groups and cohorts

  • cases

    hospitalized older patients with heart failure and delirium

    Other: Comprehensive Geriatric Assessment · Other: the Confusion Assessment Method (CAM test) or CAM-ICU · Other: Delirium Rating Scale - Revised-98 · Diagnostic Test: blood biomarkers

  • controls

    age and gender matched heart failure older patients without delirium

    Other: Comprehensive Geriatric Assessment · Other: the Confusion Assessment Method (CAM test) or CAM-ICU · Diagnostic Test: blood biomarkers

Interventions

  • OtherComprehensive Geriatric Assessment

    multidimensional assessment of cognition, physical, function, mood, social status of the participants

  • Otherthe Confusion Assessment Method (CAM test) or CAM-ICU

    standardized tool designed to quickly and accurately diagnose delirium by assessing four key features: acute mental change, inattention, and either disorganized thinking or altered consciousness. The original CAM is used for communicative patients on general wards, relying on conversation, while the CAM-ICU is adapted for critically ill, often non-verbal patients in the ICU, using non-verbal tasks and sedation scales. By providing a rapid, reliable method for identifying this often-missed condition, both tools trigger crucial medical interventions, helping to mitigate delirium's serious risks, including longer hospital stays, long-term cognitive decline, and increased mortality.

  • OtherDelirium Rating Scale - Revised-98

    The Delirium Rating Scale-Revised-98 (DRS-R-98) is a standardized, expert-rated clinical tool designed specifically to measure the severity of delirium and help distinguish it from other psychiatric disorders, such as dementia, depression, and schizophrenia. Unlike the CAM/CAM-ICU, which provides a simple "yes/no" diagnosis, the DRS-R-98 quantifies how severe a patient's delirium is at a given point in time and tracks changes in that severity over the course of the illness

  • Diagnostic testblood biomarkers

    complete blood count(to obtain systemic inflammatory index) ,triglyceride (TG) and glucose, Liver and kidney function tests and serum electrolytes level

06

What researchers measure

Primary outcomes

  1. the sensitivity and specificity of different biomarkers of delirium in heart failure older patient

    assess sensitivity and specificity of the systemic inflammatory index (SII), Rate Pressure Product (RPP), and TG/glucose ratio in predicting delirium

    Time frame: Within 24 hours of hospital admission

Secondary outcomes

  1. in hospital morbidity

    follow up cohort for possible complications like acute kidney injury, infections, or adverse drug events

    Time frame: From enrollment to the hospital discharge about 6 weeks

  2. In hospital mortality

    cohort follow up throughout hospital course and mortality recorded

    Time frame: From enrollment to hospital discharge about 6 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2026 to primary completion in Aug 2026, 6 months.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's 6 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jul 2026 → Aug 2026 and completion Aug 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2025
First posted
Dec 24, 2025
StartActual
Jan 20, 2026
Primary completionActual
Aug 1, 2026was Jul 2026
CompletionActual
Oct 1, 2026was Aug 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Nov 12, 2026
Primary completion
Jul 1, 2026→Aug 1, 2026 (actual)
Nov 12, 2026
Study completion
Aug 1, 2026→Oct 1, 2026 (actual)
Nov 12, 2026
Enrollment
100 (estimated)→70 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Not yet recruiting→Completed
    Primary completion Jul 1, 2026→Aug 1, 2026 (now actual)
    Study completion Aug 1, 2026→Oct 1, 2026 (now actual)
    Enrollment 100 (estimated)→70 (actual)
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07302737
Responsible party
Sponsor
First posted
Dec 24, 2025
Start date
Jan 20, 2026
Primary completion
Aug 1, 2026
Completion
Oct 1, 2026
Last update
Nov 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion